Scientific Library

+ HIV/AIDS - PPL-100

Dandache, S. et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16.
Wu, J.J. et al. PL-100, a Next Generation Protease Inhibitor against Drug-Resistant HIV: In Vitro and In Vivo Metabolism. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held in San Francisco, September 2006.
Wu, J.J. et al. The HIV-1 Protease Inhibitor PL-100 Has a High Genetic Barrier and Selects a Novel Patterns of Mutations. XV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications, Sitges, Spain, June 2006
Dandache, S. et al. PL-100, a Novel Protease Inhibitor with a High Genetic Barrier. XVI International AIDS Conference, Toronto, Canada, August 2006.
Wu, J. et al. PPL-100 and its derivatives, a novel class of potent human immunodeficiency virus type 1 protease inhibitors: resistance and pharmacokinetics. XIV International HIV Drug Resistance Workshop, Quebec City, Canada, June 2005.
Wu, J. et al. Pharmacological and cross-resistance profiling of PL-100 and its pro-drug, PPL-100. 6th International Workshop on Clinical Pharmacology of HIV Therapy, Quebec City, Canada, April 2005.
Sévigny, G, et al. Cross-resistance profile of the novel lysine-containing HIV-1 protease inhibitor PL-100. XIII International HIV Drug Resistance Workshop, Canary Islands, Spain, June 2004.
Stranix, B., et al. Lysine sulfonamides as Novel HIV-Protease Inhibitors: Nε-disubstituted ureas. Bioorganic and Medicinal Chemistry Letters 2004, Vol. 14, pp 3971 - 3974.
Sévigny, G, et al. Improving the resistance profile of HIV-1 protease inhibitors. Protease Targets and Drug Discovery Symposium, Philadelphia, PA, U.S.A., December 2003.
Stranix, B., et al. Lysine sulfonamides as Novel HIV-Protease Inhibitors: Optimization of the Nε-Acyl-Phenyl Spacer. Bioorganic and Medicinal Chemistry Letters 2003, Vol. 13, pp 4289 - 4292.
Stranix, B., et al. Synthesis and SAR studies of novel HIV protease inhibitors, containing a lysine backbone. 39th International Union of Pure and Applied Chemistry Congress and 86th Conference of the Canadian Society For Chemistry, Ottawa, Canada, August 2003.
Sévigny, G. et al. Antiviral activity of P-1946, a novel anti-HIV protease inhibitor. XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, June 2003.

+ HIV/AIDS - Integrase inhibitor program

Small Molecule Inhibitors of HIV-1 Integrase, XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 10-14, 2008.
Pyrazolopyridine compounds as novel HIV-1 integrase inhibitors Poster , 47th ICAAC , Chicago, September 17-20, 2007.
Novel smal molecule inhibitors of HIV-1 integrase Poster, HIV Drug Resistance Workshop , Barbados, June 12-16, 2007.

+ Prostate cancer - PCK3145

Guérin, M., et al. Synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein with in vitro and in vivo activity against non-Hodgkins lymphoma and other hematologic malignancies. ASH 49th Annual Meeting - Atlanta, Georgia, USA, December 8-11, 2007.
Slovin, S., et al. PCK3145 - A Novel Multitargeted Signaling Agent for the Treatment of Castrate Metastatic Prostate Cancer (CMPC), AACR-NCI-EORTC International Conference - San Francisco, California, U.S.A., October 22-26, 2007.
Slovin, S., et al. Phase I trial results of PCK3145 in patients (pts) with castrate metastatic prostate cancer (PC) – the US experience. ASCO Prostate Cancer - San Francisco, California, U.S.A., February 2006.
Dulude, H., et al. PCK3145 administered weekly reduces the plasma MMP-9 level in metastatic Hormone Refractory Prostate Cancer (HRPC) patients. ASCO Prostate Cancer - San Francisco, California, U.S.A., February 2006.
Annabi, B., et al. Inhibition of MMP-9 secretion by the anti-metastatic PSP94 derived peptide PCK3145 requires cell surface laminin receptor signaling. Anti-Cancer Drugs 2006, Vol. 17, pp 429-438.
Lamy, S., et al. A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signaling in endothelial cells: implication in tumor angiogenesis. Int. J. Cancer 2006, Vol. 118, pp 2350-2358.
Annabi, B., et al. A PSP94-derived peptide PCK3145 inhibits MMP-9 secretion and triggers CD44 cell surface shedding: Implications in tumor metastasis. Clinical & Experimental Metastasis 2005, Vol. 22, pp 429-439.
Panchal, C. PCK3145, a novel signal transduction inhibitor for treating late stage prostate cancer. 3rd Angiogenesis Foundation’s Annual Symposium - Boston, Massachusetts, U.S.A., October 2005
Hawkins, R.E., et al. Safety and tolerability of PCK3145, a synthetic peptide derived from prostate secretory protein 94 (PSP94) in metastatic hormone-refractory prostate cancer. Clinical Prostate Cancer 2005, Vol. 4, pp 91-99.
Wu, J., et al. Inhibition of multiple signaling pathways by PCK3145 and its implication in the treatment of prostate cancer. Prostate Cancer Foundation - Scotsdale, Arizona, U.S.A., September 2005.
Daigneault, L., et al. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. ASCO - Orlando, Florida, U.S.A., May 2005.
Garde, S., et al. Inhibition of angiogenesis and MMP-9 production by a synthetic peptide (PCK3145) in a syngeneic model of rat prostate cancer results in decreased tumor growth and skeletal metastasis in-vitro and in-vivo. AACR - Anaheim, California, U.S.A., April 2005.
Lamy, S., et al. A prostate secretory protein 94 (PSP94)-derived synthetic peptide (PCK3145) antagonizes VEGF signaling in endothelial cells: Implications in tumor angiogenesis. AACR - Anaheim, California, U.S.A., April 2005.
Daigneault, L., et al. A synthetic peptide, PCK3145, for the treatment of hormone refractory prostate cancer. ASCO Prostate Cancer - Orlando, Florida, U.S.A., February 2005.
Panchal, C., et al. Development of a novel peptide drug PCK3145 derived from the naturally occurring prostate secretory protein PSP94. INCP - Zermatt, Switzerland, November 2004.
Lemoyne, C., et al. Determination of PCK3145 (peptide) in human plasma by LC/MS/MS. AAPS - Baltimore, Maryland, U.S.A., November 2004.
Panchal, C., et al. Clinical development of a synthetic peptide, PCK3145, for treatment of Hormone Refractory Prostate Cancer patients. Prostate Cancer Foundation - Lake Tahoe, Nevada, U.S.A., October 2004
Shukeir, N., et al. A synthetic 15-mer peptide (PCK3145) derived from prostate secretory protein can reduce tumor growth, experimental skeletal metastases, and malignancy-associated hypercalcemia. Cancer Research 2004, Vol. 64, pp 5370-5377.
Hawkins, R., et al. A multiple ascending dose, open-label, phase IIa study evaluating the safety and tolerability of PCK3145administered intravenously in patients with metastatic hormone refractory prostate cancer (HRPC). ASCO - New Orleans, Louisiana, U.S.A., June 2004.
Daigneault, L., et al. Evaluation of biological activity of PCK3145 in metastatic hormone resistant prostate cancer (HRPC) using serum markers. ASCO - New Orleans, Louisiana, U.S.A., June 2004.
Dulude, H., et al. Safety, tolerability, pharmacokinetic and escalating single doses of PCK3145 in patients with metastatic hormone resistant prostatic cancer (HRPC). AACR - Orlando, Florida, U.S.A., March 2004.
Panchal, C., et al. Development of a synthetic peptide, PCK3145, for human clinical trials involving HRPC patients. CapCure, New York, New York, U.S.A., November 2003.
Shukeir, N., et al. A synthetic 15 mer peptide derived from prostate secretory protein (PSP94) can reduce tumor growth, skeletal metastases and malignancy associated hypercalcemia. AACR - Washington, District of Columbia, U.S.A. June 2003.
Shukeir, N., et al. Prostate secretory protein PSP94 decreases tumor growth and hypercalcemia of malignancy in a syngenic invivo model of prostate cancer. Cancer Research 2003, Vol. 63 pp 2072-2078.
Garde, S., et al. Prostate secretory protein (PSP94) suppresses the growth of androgen-independent prostate cell line (PC3) and xenografts by inducing apoptosis. The Prostate 1999, Vol. 38, pp 118-125.

+ Cancer - NGR-Delivery Technology

Garde, S., et al. TVT-Dox: in vivo efficacy and in vitro molecular mechanism of action. AACR 2007, Los Angeles, California, USA, April 14-18, 2007.
Wu, J.J., et al. A novel dual-targeting drug for the solid tumors and their vasculature. 2006 Miami Nature Biotechnology Winter Symposium Angiogenesis in Cancer and Vascular Disease, Miami Beach, Florida, February 2006.
Meyer, O., et al . Preclinical efficacy of tumor vasculature targeted liposomal doxorubicin. Royal Society of Canada (RSC)/ Korean Academy of Science and Technology (KAST) 3rd Bilateral Symposium: Drug Delivery Systems, Vancouver, Canada, July 2005.
Meyer, O., et al. Assay methods for binding NGR-targeted liposomal doxorubicin using cells expressing the angiogenic marker CD13. Lipids, Liposomes & Biomembranes, new technologies, UBC, Vancouver, Canada, July 2005.
Curnis, F., et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 2002 62(3):867-874
Pastorino, F. et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 2003;63(21):7400-7409